Latest Therapeutics News

Page 17 of 90
Starpharma has reached a key milestone in its collaboration with Radiopharm Theranostics, unlocking a $0.5 million option fee and advancing the partnership toward a potential $91 million licensing deal.
Ada Torres
Ada Torres
3 July 2026
Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.
Ada Torres
Ada Torres
2 July 2026
Neurotech International has received Notices of Allowance from the USPTO for two patents covering its lead drug NTI164, reinforcing its intellectual property position as it advances Phase 3 trials for autism spectrum disorder.
Ada Torres
Ada Torres
2 July 2026
Imugene reports a second complete response in its Phase 1b trial of azer-cel combined with BTK inhibitors, including the first patient with Mantle Cell Lymphoma who had failed prior BTKi therapy.
Ada Torres
Ada Torres
1 July 2026
AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.
Ada Torres
Ada Torres
1 July 2026
Chimeric Therapeutics has appointed Hawkesbury Partners to lead a strategic review aimed at exploring options to enhance shareholder value, reflecting concerns that its market cap undervalues its clinical assets and infrastructure.
Ada Torres
Ada Torres
1 July 2026
Clarity Pharmaceuticals will present compelling data at EANM 2026 demonstrating its 64Cu-SAR-bisPSMA imaging agent’s superior detection of prostate cancer recurrence and promising therapeutic results from 67Cu-SAR-bisPSMA in advanced disease.
Ada Torres
Ada Torres
29 June 2026
Skin Elements Limited has secured a $900,000 placement at a 25% discount to recent prices, bolstering its balance sheet to advance its natural biotechnology product range. The company also appointed Rod Nicholas as non-executive chairman and engaged Phoenix Global Investments for investor relations.
Ada Torres
Ada Torres
26 June 2026
4DMedical has cleared a major regulatory hurdle with the Therapeutic Goods Administration approving its CT:VQ™ lung imaging software, paving the way for commercial use across Australia and strengthening its global footprint.
Ada Torres
Ada Torres
26 June 2026
INOVIQ Limited’s CAR-exosome platform demonstrated potent tumour-killing activity in ovarian cancer cell lines, eliminating up to 90% of cancer cells within 48 hours and reinforcing its potential against hard-to-treat solid tumours.
Ada Torres
Ada Torres
25 June 2026
Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.
Ada Torres
Ada Torres
24 June 2026
The Calmer Co. has won Coles' approval for its innovative Fiji Kava® FZZR™ product, extending its Australian supermarket reach while gearing up for a broader U.S. retail rollout supported by a key brokerage partnership.
Victor Sage
Victor Sage
24 June 2026

Browse the archive

Full archive